Impact of stress on cancer metastasis

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Fidler IJ: The role of organ microenvironment in the biology and therapy of cancer metastasis. J. Cell. Biochem.101,927–936 (2007).
  Medline CASGoogle Scholar
• 2  Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation70(9–10),498–505 (2002).
  MedlineGoogle Scholar
• 3  Spiegel D, Giese-Davis J: Depression and cancer: mechanisms and disease progression. Biol. Psychiatry54(3),269–282 (2003).
  MedlineGoogle Scholar
• 4  Bukberg J, Penman D, Holland JC: Depression in hospitalized cancer patients. Psychosom. Med.46,199–212 (1984).
  Medline CASGoogle Scholar
• 5  Spiegel D: Health caring: psychosocial support for patients with cancer. Cancer74(4),1453–1457 (1994).
  Medline CASGoogle Scholar
• 6  Chida Y, Hamer M, Wardle J et al.: Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat. Clin. Pract. Oncol.5(8),466–475 (2008).▪▪ Provides an overview of the clinical studies addressing the impact of stress factors on cancer.
  MedlineGoogle Scholar
• 7  Duijts SF, Zeegers MP, Borne BV: The association between stressful life events and breast cancer risk: a meta-analysis. Int. J. Cancer107(6),1023–1029 (2003).
  Medline CASGoogle Scholar
• 8  Lillberg K, Verkasalo P, Kaprio J et al.: Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am. J. Epidemiol.157(5),415–423 (2003).
  MedlineGoogle Scholar
• 9  Geyer S: Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. J. Psychosom. Res.35(2–3),355–363 (1991).
  Medline CASGoogle Scholar
• 10  Michael YL, Carlson NE, Chlebowski RT et al.: Influence of stressors on breast cancer incidence in the Women’s Health Initiative. Health Physiol.28,137–146 (2009).
  Google Scholar
• 11  Steel JL GD, Gamblin TC, Olek MC, Carr BI: Depression, immunity, and survival in patients with hepatobiliary carcinoma. J. Clin. Oncol.25,2397–2405 (2007).
  MedlineGoogle Scholar
• 12  Satin JR, Linden W, Phillips MJ: Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer22,5349–5361 (2009).
  Google Scholar
• 13  Everson SA, Goldberg DE, Kaplan GA et al.: Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom. Med.58(2),113–121 (1996).
  Medline CASGoogle Scholar
• 14  Stommel M, Given BA, Given CW: Depression and functional status as predictors of death among cancer patients. Cancer94(10),2719–2727 (2002).
  MedlineGoogle Scholar
• 15  Watson M, Haviland JS, Greer S et al.: Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet354(9187),1331–1336 (1999).
  Medline CASGoogle Scholar
• 16  Buccheri G: Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur. Respir. J.11(1),173–178 (1998).
  Medline CASGoogle Scholar
• 17  Cohen S, Willis TA: Stress, social support, and the buffering hypothesis. Psychol. Bull.98,310–357 (1985).
  Medline CASGoogle Scholar
• 18  Funch DP, Marshall J: The role of stress, social support and age in survival from breast cancer. J. Psychosom. Res.27,77–83 (1983).
  Medline CASGoogle Scholar
• 19  Marshall JR, Funch DP: Social environment and breast cancer. A cohort analysis of patient survival. Cancer52(8),1546–1550 (1983).
  Medline CASGoogle Scholar
• 20  Maunsell E, Brisson J, Deschenes L: Social support and survival among women with breast cancer. Cancer76(4),631–637 (1995).
  Medline CASGoogle Scholar
• 21  Giraldi T, Rodani MG, Cartei G et al.: Psychosocial factors and breast cancer: a 6-year Italian follow-up study. Psychother. Psychosom.66(5),229–236 (1997).
  Medline CASGoogle Scholar
• 22  Butow PN, Hiller JE, Price MA et al.: Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer. J. Psychosom. Res.49(3),169–181 (2000).
  Medline CASGoogle Scholar
• 23  Kroenke CH, Kubzansky LD, Schernhammer ES et al.: Social networks, social support, and survival after breast cancer diagnosis. J. Clin. Oncol.24(7),1105–1111 (2006).
  MedlineGoogle Scholar
• 24  Sapolsky RM: Why Zebras Don’t Get Ulcers: A Guide to Stress, Stress-Related Diseases, and Coping. WH Freeman and Co., NY, USA (1998).
  Google Scholar
• 25  Chrousos G: Stress and disorders of the stress system. Nat. Rev. Endocrinol.5,374–381 (2009).
  Medline CASGoogle Scholar
• 26  McEwen B: Stress and health: relevance to persian gulf veterans? Presented at: International Society for Traumatic Stress Studies Annual Meeting 1998. Washington, DC, USA, 21–23 November 1998.
  Google Scholar
• 27  Schmidt C, Kraft K: β-endorphin and catecholamine concentrations during chronic and acute stress in intensive care patients. Eur. J. Med. Res.1(11),528–532 (1996).
  Medline CASGoogle Scholar
• 28  Rupp H, Dhalla KS, Dhalla NS: Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J. Cardiovasc. Pharmacol.24(Suppl. 1),S16–S24 (1994).
  Medline CASGoogle Scholar
• 29  Rupp H, Jacob R: Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? Med. Hypotheses44(3),217–225 (1995).
  Medline CASGoogle Scholar
• 30  Puglisi-Allegra S, Imperato A, Angelucci L et al.: Acute stress induces time-dependent responses in dopamine mesolimbic system. Brain Res.554(1–2),217–222 (1991).
  Medline CASGoogle Scholar
• 31  Imperato A, Angelucci L, Casolini P et al.: Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Res.577(2),194–199 (1992).
  Medline CASGoogle Scholar
• 32  Seeman TE, Berkman LF, Blazer D et al.: Social ties and support and neuroendocrine function: the McArthur studies of successful aging. Ann. Behav. Med.16(95–106), (1994).
  Google Scholar
• 33  Seeman TE, McEwen BS: Impact of social environment characteristics on neuroendocrine regulation. Psychosom. Med.58(5),459–471 (1996).
  Medline CASGoogle Scholar
• 34  Seeman TE SB, Rowe JW, Horwitz RI, McEwen B: Price of adaptation-allostatic load and its health consequences. Arch. Intern. Med.157,2259–2268 (1997).
  Medline CASGoogle Scholar
• 35  Kiecolt-Glaser JK BC, Glaser R, Malarkey WB: Love, marriage, and divorce: newlyweds’ stress hormones foreshadow relationship changes. J. Consult. Clin. Psychol.71,176–188 (2003).
  MedlineGoogle Scholar
• 36  Tyrka AR, Wier L, Price LH et al.: Childhood parental loss and adult hypothalamic–pituitary–adrenal function. Biol. Psychiatry63,1147–1154 (2008).
  Medline CASGoogle Scholar
• 37  Bevans K, Cerbone A, Overstreet S: Relations between recurrent trauma exposure and recent life stress and salivary cortisol among children. Develop. Psychopathol.20,257–272 (2008).
  MedlineGoogle Scholar
• 38  Hughes J, Watkins L, Blumenthal JA et al.: Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J. Psychosom. Res.57,353–358 (2004).
  MedlineGoogle Scholar
• 39  Grossman F, Potter WZ: Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. Psychiatry Res.87,21–27 (1999).
  Medline CASGoogle Scholar
• 40  Lake C, Pickar D, Ziegler MG et al.: High plasma norepinephrine levels in patients with major affective disorder. Am. J. Psychiatry139,1315–1318 (1982).
  Medline CASGoogle Scholar
• 41  McEwen B: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev.87,873–904 (2007).
  MedlineGoogle Scholar
• 42  Ebner K RN, Saria A, Singewald N: Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl Acad. Sci. USA101,4280–4285 (2004).
  Medline CASGoogle Scholar
• 43  Lakshmanan J: Nerve growth factor levels in mouse serum: variations due to stress. Neurochem. Res.12,393–397 (1987).
  Medline CASGoogle Scholar
• 44  Lara HE, Porcile A, Espinoza J et al.: Release of norepinephrine from human ovary: coupling to steroidogenic response. Endocrine15(2),187–192 (2001).
  Medline CASGoogle Scholar
• 45  Greenwald G, Roy S: Follicular development and its control. In: The Physiology of Reproduction. Knobil E, Neill J (Eds). Raven Press, NY, USA, 629–724 (1994).
  Google Scholar
• 46  Nankova B, Kvetnansky R, Hiremagalur B et al.: Immobilization stress elevates gene expression for catecholamine biosynthetic enzymes and some neuropeptides in rat sympathetic ganglia: effects of adrenocorticotropin and glucocorticoids. Endocrinology137(12),5597–5604 (1996).
  Medline CASGoogle Scholar
• 47  Paredes A, Galvez A, Leyton V et al.: Stress promotes development of ovarian cysts in rats: the possible role of sympathetic nerve activation. Endocrine8(3),309–315 (1998).
  Medline CASGoogle Scholar
• 48  Lara HE, Dorfman M, Venegas M et al.: Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: studies on norepinephrine release. Microsc. Res. Tech.59(6),495–502 (2002).
  Medline CASGoogle Scholar
• 49  Maestroni GJ: Neurohormones and catecholamines as functional components of the bone marrow microenvironment. Ann. NY Acad. Sci.917,29–37 (2000).
  Medline CASGoogle Scholar
• 50  Kobilka B: Adrenergic receptors as models for G protein-coupled receptor. Annu. Rev. Neurosci.15,87–114 (1992).
  Medline CASGoogle Scholar
• 51  Pullar CE, Isseroff RR: The β-2-adrenergic receptor activates pro-migratory and pro-proliferative pathways in dermal fibroblasts via divergent mechanisms. J. Cell Sci.119(Pt 3),592–602 (2006).
  Medline CASGoogle Scholar
• 52  Lai LP Mitchell J: β2-adrenergic receptors expressed on murine chondrocytes stimulate cellular growth and inhibit the expression of Indian hedgehog and collagen type X. J. Cell Biochem.104,545–553 (2008).
  Medline CASGoogle Scholar
• 53  Bylund D, Blaxall HS, Iversen LJ, Caron MG, Lefkowitz RJ, Lomasney JW: Pharmacological characteristics of α 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol. Pharmacol.42,1–5 (1992).
  Medline CASGoogle Scholar
• 54  Fernando M, Heaney AP: α1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol. Endocrinol.19(12),3085–3096 (2005).
  Medline CASGoogle Scholar
• 55  Badino GR, Novelli A, Girardi C et al.: Evidence for functional β-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol. Res.33(4–5),255–260 (1996).
  Medline CASGoogle Scholar
• 56  Lutgendorf SK, Cole S, Costanzo E et al.: Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res.9(12),4514–4521 (2003).
  Medline CASGoogle Scholar
• 57  McDonald PH, Lefkowitz RJ: β-arrestins: new roles in regulating heptahelical receptors functions. Cell Signal13(10),683–689 (2001).
  Medline CASGoogle Scholar
• 58  Dixon RA, Kobilka BK, Strader DJ et al.: Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature321(6065),75–79 (1986).
  Medline CASGoogle Scholar
• 59  Emorine LJ, Marullo S, Briend-Sutren MM et al.: Molecular characterization of the human β-3-adrenergic receptor. Science245(4922),1118–1121 (1989).
  Medline CASGoogle Scholar
• 60  Frielle T, Collins S, Daniel KW et al.: Cloning of the cDNA for the human β 1-adrenergic receptor. Proc. Natl Acad. Sci. USA84(22),7920–7924 (1987).
  Medline CASGoogle Scholar
• 61  Thaker PH, Han LY, Kamat AA et al.: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med.12(8),939–944 (2006).▪▪ First study to demonstrate the impact of stress hormones on cancer angiogenesis.
  Medline CASGoogle Scholar
• 62  Rhen T Cidlowski J: Anti-inflammatory action of glucocorticoids – new mechanisms for old drugs. N. Engl. J. Med.353(16),1711 (2005).
  Medline CASGoogle Scholar
• 63  Newton R: Molecular mechanisms of glucocorticoid action: what is important? Thorax55(7),603–613 (2000).
  Medline CASGoogle Scholar
• 64  Pazirandeh A , Xue Y, Prestegaard T et al.: Effects of altered glucocorticoid sensitivity in the T cell lineage on thymocyte and T cell homeostasis. FASEB J.16(7),727–729 (2002).
  Medline CASGoogle Scholar
• 65  Chrousos GP, Gold PW: The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA267(9),1244–1252 (1992).
  Medline CASGoogle Scholar
• 66  Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev.21(1),55–89 (2000).
  Medline CASGoogle Scholar
• 67  Antoni MH, Cruess S, Cruess DG et al.: Cognitive–behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men. Ann. Behav. Med.22(1),29–37 (2000).
  Medline CASGoogle Scholar
• 68  Sephton S, Spiegel D: Circadian disruption in cancer: a neuroendocrine–immune pathway from stress to disease? Brain Behav. Immun.17(5),321–328 (2003).
  Medline CASGoogle Scholar
• 69  Sephton SE, Sapolsky RM, Kraemer HC et al.: Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl Cancer Inst.92(12),994–1000 (2000).▪ Important clinical study addressing the role of cortisol in breast cancer patients.
  Medline CASGoogle Scholar
• 70  Schernhammer ES, Laden F, Speizer FE et al.: Night-shift work and risk of colorectal cancer in the nurses’ health study. J. Natl Cancer Inst.95(11),825–828 (2003).
  MedlineGoogle Scholar
• 71  Kawamura A, Tamaki N, Kokunai T: Effect of dexamethasone on cell proliferation of neuroepithelial tumor cell lines. Neurol. Med. Chir. (Tokyo)38(10),633–638; discussion 638–640 (1998).
  Medline CASGoogle Scholar
• 72  Nakane T, Szentendrei T, Stern L et al.: Effects of IL-1 and cortisol on β-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells. J. Immunol.145(1),260–266 (1990).
  Medline CASGoogle Scholar
• 73  Sheridan JF, Feng NG, Bonneau RH et al.: Restraint stress differentially affects anti-viral cellular and humoral immune responses in mice. J. Neuroimmunol.31(3),245–255 (1991).
  Medline CASGoogle Scholar
• 74  Padgett DA, Marucha PT, Sheridan JF: Restraint stress slows cutaneous wound healing in mice. Brain Behav. Immun.12(1),64–73 (1998).
  Medline CASGoogle Scholar
• 75  Padgett DA, Sheridan JF, Dorne J et al.: Social stress and the reactivation of latent herpes simplex virus type 1. Proc. Natl Acad. Sci. USA95(12),7231–7235 (1998).
  Medline CASGoogle Scholar
• 76  Iwakabe K, Shimada M, Ohta A et al.: The restraint stress drives a shift in Th1/Th2 balance toward Th2-dominant immunity in mice. Immunol. Lett.62(1),39–43 (1998).
  Medline CASGoogle Scholar
• 77  Fiserova A, Starec M, Kuldova M et al.: Effects of D2-dopamine and α-adrenoceptor antagonists in stress induced changes on immune responsiveness of mice. J. Neuroimmunol.130(1–2),55–65 (2002).
  Medline CASGoogle Scholar
• 78  Nukina H, Sudo N, Aiba Y et al.: Restraint stress elevates the plasma interleukin-6 levels in germ-free mice. J. Neuroimmunol.115(1–2),46–52 (2001).
  Medline CASGoogle Scholar
• 79  Zhou D, Kusnecov AW, Shurin MR et al.: Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic–pituitary–adrenal axis. Endocrinology133(6),2523–2530 (1993).
  Medline CASGoogle Scholar
• 80  Zorzet S, Perissin L, Rapozzi V et al.: Restraint stress reduces the antitumor efficacy of cyclophosphamide in tumor-bearing mice. Brain Behav. Immun.12(1),23–33 (1998).
  Medline CASGoogle Scholar
• 81  Steplewski Z, Vogel WH, Ehya H et al.: Effects of restraint stress on inoculated tumor growth and immune response in rats. Cancer Res.45(10),5128–5133 (1985).
  Medline CASGoogle Scholar
• 82  Cao L, Filipov NM, Lawrence DA: Sympathetic nervous system plays a major role in acute cold/restraint stress inhibition of host resistance to Listeria monocytogenes. J. Neuroimmunol.125(1–2),94–102 (2002).
  Medline CASGoogle Scholar
• 83  Steplewski Z, Goldman PR, Vogel WH: Effect of housing stress on the formation and development of tumors in rats. Cancer Lett.34(3),257–261 (1987).
  Medline CASGoogle Scholar
• 84  Tjurmina OA, Armando I, Saavedra JM et al.: Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology143(12),4520–4526 (2002).
  Medline CASGoogle Scholar
• 85  Kvetnansky R, Fukuhara K, Pacak K et al.: Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats. Endocrinology133(3),1411–1419 (1993).
  Medline CASGoogle Scholar
• 86  Ghoshal K, Wang Y, Sheridan JF, Jacob ST: Metallothionein induction in response to restraint stress. Transcriptional control, adaptation to stress, and role of glucocorticoid. J. Biol. Chem.273,27904–27910 (1998).
  Medline CASGoogle Scholar
• 87  Ben-Eliyahu S, Yirmiya R, Liebeskind JC, Taylor AN, Gale RP: Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav. Immun.5(2),193–205 (1991).
  Medline CASGoogle Scholar
• 88  Ben-Eliyahu S, Page GG, Yirmiya R et al.: Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int. J. Cancer.80(6),880–888 (1999).
  Medline CASGoogle Scholar
• 89  Page GG, Ben-Eliyahu S: A role for NK-cells in greater susceptibility of young rats to metastatic formation. Develop. Comp. Immunol.23(1),87–96 (1999).
  Medline CASGoogle Scholar
• 90  Page GG, Ben-Eliyahu S, Yirmiya R et al.: Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain54(1),21–28 (1993).
  Medline CASGoogle Scholar
• 91  Ben-Eliyahu S, Shakhar G, Rosenne E et al.: Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology91(3),732–740 (1999).
  Medline CASGoogle Scholar
• 92  Hermes GL, Delgado B, Tretiakova M et al.: Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc. Natl Acad. Sci. USA106(52),22393–22398 (2009).
  Medline CASGoogle Scholar
• 93  Hermes GL, Rosenthal L, Montag A, McClintock MK: Social isolation and the inflammatory response: sex differences in the enduring effects of a prior stressor. Am. J. Physiol. Regul. Integr. Comp. Physiol.290(2),R273–R282 (2006).
  Medline CASGoogle Scholar
• 94  Sharp J, Zammit T, Azar T, Lawson D: Stress-like responses to common procedures in individually and group-housed female rats. Contemp. Top. Lab. Anim. Sci.42,9–18 (2003).
  Medline CASGoogle Scholar
• 95  Fisher ER, Fisher B: Recent observations on concepts of metastasis. Arch. Pathol.83(4),321–324 (1967).
  Medline CASGoogle Scholar
• 96  Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? – G.H.A. Clowes Memorial Award Lecture. Cancer Res.46(2),467–473 (1986).
  Medline CASGoogle Scholar
• 97  Liotta LA: Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res.46(1),1–7 (1986).
  Medline CASGoogle Scholar
• 98  Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer3(6),453–458 (2003).▪ Important review of the metastatic process.
  Medline CASGoogle Scholar
• 99  Folkman J: Toward an understanding of angiogenesis: search and discovery. Perspect. Biol. Med.29(1),10–36 (1985).
  Medline CASGoogle Scholar
• 100  Langley RR, Fidler IJ: Tumor cell–organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev.28(3),297–321 (2007).
  Medline CASGoogle Scholar
• 101  Senger DR, Galli SJ, Dvorak AM et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science219(4587),983–985 (1983).
  Medline CASGoogle Scholar
• 102  Spannuth WA, Sood AK, Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol.5(4),194–204 (2008).
  Medline CASGoogle Scholar
• 103  Ferrara N: Vascular endothelial growth factor. Eur. J. Cancer32A(14),2413–2422 (1996).
  Medline CASGoogle Scholar
• 104  Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr. Rev.18(1),4–25 (1997).
  Medline CASGoogle Scholar
• 105  Fredriksson JM, Lindquist JM, Bronnikov GE et al.: Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoreceptor/cAMP/protein kinase-A pathway involving Src but independently of ERK1/2. J. Biol. Chem.275(18),13802–13811 (2000).
  Medline CASGoogle Scholar
• 106  Yang E, Donovan EL, Benson DM, Glaser R: VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav. Immun.22,318–322 (2008).
  MedlineGoogle Scholar
• 107  Lutgendorf SK, Johnsen EL, Cooper B et al.: Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer95(4),808–815 (2002).
  Medline CASGoogle Scholar
• 108  Lutgendorf SK, Lamkin DM, Jennings NB et al.: Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin. Cancer Res.14,6839–6846. (2008).
  Medline CASGoogle Scholar
• 109  Sharma A, Greenman J, Sharp DM, Walker LG, Monson JR: Vascular endothelial factor and psychosocial factors in colorectal cancer. Psychooncology17(1),66–73 (2008).
  Medline CASGoogle Scholar
• 110  Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM: Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer104,305–313 (2005).
  MedlineGoogle Scholar
• 111  Van Snick J: Interleukin-6: an overview. Annu. Rev. Immunol.8,253–278 (1990).
  Medline CASGoogle Scholar
• 112  Obata NH, Tamakoshi K, Shibata K et al.: Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res.17(1A),337–342 (1997).
  Medline CASGoogle Scholar
• 113  Wu S, Rodabaugh K, Martinez-Maza O et al.: Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α. Am. J. Obstet. Gynecol.166(3),997–1007 (1992).
  Medline CASGoogle Scholar
• 114  Nilsson MB, Langley RR, Fidler IJ: Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res.65(23),10794–10800 (2005).
  Medline CASGoogle Scholar
• 115  Nilsson MB, Armaiz-Pena G, Takahashi R et al.: Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J. Biol. Chem.282(41),29919–29926 (2007).
  Medline CASGoogle Scholar
• 116  Yang EV, Sood AK, Chen M et al.: Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res.66(21),10357–10364 (2006).
  Medline CASGoogle Scholar
• 117  Landen CN, Lin YG, Armaiz Pena GN et al.: Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res.67(21),10389–10396 (2007).
  Medline CASGoogle Scholar
• 118  Machein MR, Kullmer J, Ronicke V et al.: Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol. Appl. Neurobiol.25(2),104–112 (1999).
  Medline CASGoogle Scholar
• 119  Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res.50(19),6130–6138 (1990).
  Medline CASGoogle Scholar
• 120  Flaxman BA, Harper RA: In vitro analysis of the control of keratinocyte proliferation in human epidermis by physiologic and pharmacologic agents. J. Invest. Dermatol.65(1),52–59 (1975).
  Medline CASGoogle Scholar
• 121  Vandewalle B, Revillion F, Lefebvre J: Functional β-adrenergic receptors in breast cancer cells. J. Cancer Res. Clin. Oncol.116(3),303–306 (1990).
  Medline CASGoogle Scholar
• 122  Marchetti B, Spinola PG, Pelletier G et al.: A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of β-adrenergic receptors and correlation with tumor growth. J. Steroid Biochem. Mol. Biol.38(3),307–320 (1991).
  Medline CASGoogle Scholar
• 123  Abramovitch R, Tavor E, Jaco Hirsch J et al.: A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res.64(4),1338–1346 (2004).
  Medline CASGoogle Scholar
• 124  Lang K, Drell TL 4th, Lindecke A et al.: Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer112(2),231–238 (2004).
  Medline CASGoogle Scholar
• 125  Jean D, Bar-Eli M: Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol. Cell. Biochem.212(1–2),19–28 (2000).
  Medline CASGoogle Scholar
• 126  Scarparo AC, Sumida D, Patrao MT et al.: Catecholamine effects on human melanoma cells evoked by α1-adrenoceptors. Arch. Dermatol. Res.296(3),112–119 (2004).
  Medline CASGoogle Scholar
• 127  Pifl C, Zezula J, Spittler A et al.: Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J.15(9),1607–1609 (2001).
  Medline CASGoogle Scholar
• 128  Cox ME, Deeble PD, Lakhani S et al.: Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res.59(15),3821–3830 (1999).
  Medline CASGoogle Scholar
• 129  Cohen RJ, Glezerson G, Haffejee Z: Neuroendocrine cells – a new prognostic parameter in prostate cancer. Br. J. Urol.68(3),258–262 (1991).
  Medline CASGoogle Scholar
• 130  Theodorescu D, Broder SR, Boyd JC et al.: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer80(11),2109–2119 (1997).
  Medline CASGoogle Scholar
• 131  diSant’Agnese PA: Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol.23(3),287–296 (1992).
  MedlineGoogle Scholar
• 132  Zhao XY, Malloy PJ, Krishnan AV et al.: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med.6(6),703–706 (2000).
  Medline CASGoogle Scholar
• 133  Simon WE, Albrecht M, Trams G et al.: In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J. Natl Cancer Inst.73(2),313–321 (1984).
  Medline CASGoogle Scholar
• 134  Boudreau N, Bissell MJ: Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell. Biol.10(5),640–646 (1998).
  Medline CASGoogle Scholar
• 135  Biology of the Extracellular Matrix (2nd edition). Hay ED (Ed.). Plenum Press, NY, USA (1991).
  Google Scholar
• 136  Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell69(1),11–25 (1992).
  Medline CASGoogle Scholar
• 137  Mercurio AM, Rabinovitz I: Towards a mechanistic understanding of tumor invasion – lessons from the α6β-4 integrin. Semin. Cancer Biol.11(2),129–141 (2001).
  Medline CASGoogle Scholar
• 138  Kawasaki H, Springett GM, Mochizuki N et al.: A family of cAMP-binding proteins that directly activate Rap1. Science282(5397),2275–2279 (1998).
  Medline CASGoogle Scholar
• 139  de Rooij J, Zwartkruis FJ, Verheijen MH et al.: Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature396(6710),474–477 (1998).
  Medline CASGoogle Scholar
• 140  Rangarajan S, Enserink JM, Kuiperij HB et al.: Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the β2-adrenergic receptor. J. Cell Biol.160(4),487–493 (2003).
  Medline CASGoogle Scholar
• 141  Enserink JM, Price LS, Methi T et al.: The cAMP–Epac–Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the α3β1 integrin but not the α6β4 integrin. J. Biol. Chem.279(43),44889–44896 (2004).
  Medline CASGoogle Scholar
• 142  Yang EV, Bane CM, MacCallum RC et al.: Stress-related modulation of matrix metalloproteinase expression. J. Neuroimmunol.133(1–2),144–150 (2002).
  Medline CASGoogle Scholar
• 143  Wu W, Yamaura T, Murakami K et al.: Involvement of TNF-α in enhancement of invasion and metastasis of colon 26-L5 carcinoma cells in mice by social isolation stress. Oncol. Res.11(10),461–469 (1999).
  Medline CASGoogle Scholar
• 144  Entschladen F, Lang K, Drell TL et al.: Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol. Immunother.51(9),467–482 (2002).
  Medline CASGoogle Scholar
• 145  Masur K, Niggemann B, Zanker KS et al.: Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by β-blockers. Cancer Res.61(7),2866–2869 (2001).
  Medline CASGoogle Scholar
• 146  Joseph J, Niggemann B, Zaenker KS et al.: The neurotransmitter γ-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res.62(22),6467–6469 (2002).
  Medline CASGoogle Scholar
• 147  Sood AK, Bhatty R, Kamat AA et al.: Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res.12(2),369–375 (2006).
  Medline CASGoogle Scholar
• 148  Drell T, Joseph J, Lang K et al.: Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res. Treat.80(1),63–70 (2003).
  Medline CASGoogle Scholar
• 149  Pollard J: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer4,71–78 (2004).
  Medline CASGoogle Scholar
• 150  Coussens LM Werb Z: Inflammation and cancer. Nat. Rev. Cancer420,860–867 (2002).
  CASGoogle Scholar
• 151  Chan AS, Ng LW, Poon LS, Chan WW, Wong YH: Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress. Apoptosis12,167–179 (2007).
  Medline CASGoogle Scholar
• 152  Sastry K: Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J. Biol. Chem.282,14094–14100 (2007).
  Medline CASGoogle Scholar
• 153  Distelhorst CW: Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ.9(1),6–19 (2002).
  Medline CASGoogle Scholar
• 154  Herr I, Ucur E, Herzer K et al.: Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res.63(12),3112–3120 (2003).
  Medline CASGoogle Scholar
• 155  Wu W, Chaudhuri S, Brickley DR et al.: Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res.64(5),1757–1764 (2004).
  Medline CASGoogle Scholar
• 156  Zhang C, Kolb A, Buchler P et al.: Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer6,61(2006).
  Medline CASGoogle Scholar
• 157  Bekasi S, Zalatnai A: Overexpression of glucocorticoid receptor in human pancreatic cancer and in xenografts. An immunohistochemical study. Pathol. Oncol. Res.15(4),561–566 (2009).
  Medline CASGoogle Scholar
• 158  Zhang C, Kolb A, Mattern J et al.: Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett.242(1),104–111 (2006).
  Medline CASGoogle Scholar
• 159  Zhang C, Beckermann B, Kallifatidis G et al.: Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int. J. Oncol.29(5),1295–1301 (2006).
  Medline CASGoogle Scholar
• 160  Zhang C, Marme A, Wenger T et al.: Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int. J. Oncol.28(2),551–558 (2006).
  MedlineGoogle Scholar
• 161  Zhang C, Wenger T, Mattern J et al.: Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol. Ther.6(2),278–287 (2007).
  Medline CASGoogle Scholar
• 162  Sood AK, Armaiz-Pena GN, Halder J et al.: Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J. Clin. Invest.120(5),1515–1523 (2010).
  Medline CASGoogle Scholar
• 163  Dave JR, Anderson SM, Saviolakis GA et al.: Chronic sustained stress increases levels of anterior pituitary prolactin mRNA. Pharmacol. Biochem. Behav.67(3),423–431 (2000).
  Medline CASGoogle Scholar
• 164  Almeida SA, Petenusci SO, Franci JA et al.: Chronic immobilization-induced stress increases plasma testosterone and delays testicular maturation in pubertal rats. Andrologia32(1),7–11 (2000).
  Medline CASGoogle Scholar
• 165  Young WS 3rd, Lightman SL: Chronic stress elevates enkephalin expression in the rat paraventricular and supraoptic nuclei. Brain Res. Mol. Brain Res.13(1–2),111–117 (1992).
  Medline CASGoogle Scholar
• 166  Glavin GB, Szabo S: Dopamine in gastrointestinal disease. Dig. Dis. Sci.35(9),1153–1161 (1990).
  Medline CASGoogle Scholar
• 167  Mezey E, Eisenhofer G, Hansson S et al.: Dopamine produced by the stomach may act as a paracrine/autocrine hormone in the rat. Neuroendocrinology67(5),336–348 (1998).
  Medline CASGoogle Scholar
• 168  Thaker PH, Sood AK: Neuroendocrine influences on cancer biology. Semin. Cancer Biol.18,164–170 (2007).
  MedlineGoogle Scholar
• 169  Basu S, Nagy JA, Pal S et al.: The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med.7(5),569–574 (2001).
  Medline CASGoogle Scholar
• 170  Teunis MA, Kavelaars A, Voest E et al.: Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J.16(11),1465–1467 (2002).
  Medline CASGoogle Scholar
• 171  Chakroborty D, Sarkar C, Basu B et al.: Catecholamines regulate tumor angiogenesis. Cancer Res.69(9),3727–3730 (2009).
  Medline CASGoogle Scholar
• 172  Basu S, Sarkar C, Chakroborty D et al.: Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res.64,5551–5555 (2004).
  Medline CASGoogle Scholar
• 173  Chakroborty D, Sarkar C, Mitra RB et al.: Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res.10(13),4349–4356 (2004).
  Medline CASGoogle Scholar
• 174  Sarkar C, Chakroborty D, Chowdhury UR et al.: Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res.14(8),2502–2510 (2008).
  Medline CASGoogle Scholar
• 175  Chakroborty D, Chowdhury UR, Sarkar C et al.: Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J. Clin. Invest.118(4),1380–1389 (2008).
  Medline CASGoogle Scholar
• 176  Moreno-Smith M, Armaiz-Pena GN, Allen JK et al.: Dopamine blocks stress-mediated tumor growth in ovarian carcinoma. Presented at: 100th Annual Meeting of American Association for Cancer Resesarch. Denver, CL, USA, 18–22 April 2009.
  Google Scholar
• 177  Clevenger CV, Furth PA, Hankinson SE et al.: The role of prolactin in mammary carcinoma. Endocr. Rev.24(1),1–27 (2003).
  Medline CASGoogle Scholar
• 178  Ben-Jonathan N, Liby K, McFarland M et al.: Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol. Metab.13(6),245–250 (2002).
  Medline CASGoogle Scholar
• 179  Vonderhaar BK: Prolactin in human breast cancer development. In: Endocrine Oncology. Stephen PE (Ed.). Humana Press, NJ, USA, 101–120 (2000).
  Google Scholar
• 180  Chen WY, Ramamoorthy P, Chen N et al.: A human prolactin antagonist, HPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res.5(11),3583–3593 (1999).
  Medline CASGoogle Scholar
• 181  Richert MM, Decker K, Anderson SM: Mechanisms underlying consitutive activation of Akt in breast cancer cell lines. Presented at: 83rd Annual Meeting of the Endocrine Society. Denver, CO, USA, 20–23 June 2001.
  Google Scholar
• 182  Maus MV, Reilly SC, Clevenger CV: Prolactin as a chemoattractant for human breast carcinoma. Endocrinology140(11),5447–5450 (1999).
  Medline CASGoogle Scholar
• 183  Ben-Jonathan N, Hnasko R: Dopamine as a prolactin inhibitor. Endocr. Rev.22(6),724–763 (2001).
  Medline CASGoogle Scholar
• 184  Grewen KM, Girdler SS, Amico J, Light KC: Effects of partner support on resting oxytocin, cortisol, norepinephrine, and blood pressure before and after warm partner contact. Psychosom. Med.67(4),531–538 (2005).
  Medline CASGoogle Scholar
• 185  McCarthy MM, McDonald CH, Brooks PJ, Goldman D: An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol. Behav.60(5),1209–1215 (1996).
  Medline CASGoogle Scholar
• 186  Jezova D, Skultetyova I, Vedhara K et al.: Vasopressin and oxytocin in stress. Ann. NY Acad. Sci.771,192–203 (1995).
  Medline CASGoogle Scholar
• 187  Pequeux C, Keegan BP, Hagelstein MT et al.: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr. Relat. Cancer11(4),871–885 (2004).
  Medline CASGoogle Scholar
• 188  Cassoni P, Marrocco T, Deaglio S et al.: Biological relevance of oxytocin and oxytocin receptors in cancer cells and primary tumors. Ann. Oncol.12(Suppl. 2),S37–S39 (2001).
  MedlineGoogle Scholar
• 189  Taylor AH, Ang VT, Jenkins JS et al.: Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res.50(24),7882–7886 (1990).
  Medline CASGoogle Scholar
• 190  Bussolati GC: The oxytocin/oxytocin receptor system – expect the unexpected. Endocrinology142(4),1377–1379 (2001).
  Medline CASGoogle Scholar
• 191  Reversi A, Cassoni P, Chini B: Oxytocin receptor signaling in myoepithelial and cancer cells. J. Mammary Gland Biol. Neoplasia10(3),221–229 (2006).
  Google Scholar
• 192  Péqueux C, Breton C, Hendrick JC et al.: Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling. Cancer Res.4623–4629 (2002).
  MedlineGoogle Scholar
• 193  Mantyh P: Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiatry63,6–10 (2002).
  Medline CASGoogle Scholar
• 194  Kramer MS, Cutler N, Feighner J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science281,1640–1645 (1998).
  Medline CASGoogle Scholar
• 195  Ruff M, Schiffmann E, Terranova V et al.: Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis. Clin. Immunol. Immunopathol.37(3),387–396 (1985).
  Medline CASGoogle Scholar
• 196  Dragos D, Tanasescu MD: The effect of stress on the defense systems. J. Med. Life3(1),10–18 (2010).
  MedlineGoogle Scholar
• 197  Dhabhar FS, Saul AN, Daugherty C et al.: Short-term stress enhances cellular immunity and increases early resistance to squamous cell carcinoma. Brain Behav. Immun.24(1),127–137 (2010).
  Medline CASGoogle Scholar
• 198  Knutson KL Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother.54,721–728 (2005).
  Medline CASGoogle Scholar
• 199  Webster JI, Tonelli L, Sternberg EM: Neuroendocrine regulation of immunity. Annu. Rev. Immunol.20,125–163 (2002).
  Medline CASGoogle Scholar
• 200  Calcagni E, Elenkov I: Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann. NY Acad. Sci.1069,62–76 (2006).
  Medline CASGoogle Scholar
• 201  Kryczek I, Wei S, Zou L et al.: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol.178(11),6730–6733 (2007).
  Medline CASGoogle Scholar
• 202  Zhang B, Rong R, Wei H et al.: The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun.374(3),533–537 (2008).
  Medline CASGoogle Scholar
• 203  Curiel TJ: Regulatory T cells and treatment of cancer. Curr. Opin. Immunol.20(2),241–246 (2008).
  Medline CASGoogle Scholar
• 204  Vedhara K, Cox NK, Wilcock GK et al.: Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. Lancet353(9153),627–631 (1999).
  Medline CASGoogle Scholar
• 205  Kiecolt-Glaser JK, Ricker D, George J et al.: Urinary cortisol levels, cellular immunocompetency, and loneliness in psychiatric inpatients. Psychosom. Med.46(1),15–23 (1984).
  Medline CASGoogle Scholar
• 206  Aloyz RS, Bamji SX, Pozniak CD et al.: p53 is essential for developmental neuron death as regulated by the TRKA and p75 neurotrophin receptors. J. Cell Biol.143(6),1691–1703 (1998).
  Medline CASGoogle Scholar
• 207  Elenkov I: Systemic stress-induced Th2 shift and its clinical implications. J. Int. Rev. Neurobiol.52,163–186 (2002).
  Medline CASGoogle Scholar
• 208  Almog B, Fainaru O, Gamzu R et al.: Placental apoptosis in discordant twins. Placenta23(4),331–336 (2002).
  Medline CASGoogle Scholar
• 209  Madden KS, Sanders VM, Felten DL: Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu. Rev. Pharmacol. Toxicol.35,417–448 (1995).
  Medline CASGoogle Scholar
• 210  Brodde OE, Engel G, Hoyer D et al.: The β-adrenergic receptor in human lymphocytes: subclassification by the use of a new radio-ligand ± 125 iodocyanopindolol. Life Sci.29(21),2189–2198 (1981).
  Medline CASGoogle Scholar
• 211  Fuchs BA, Campbell KS, Munson AE: Norepinephrine and serotonin content of the murine spleen: its relationship to lymphocyte β-adrenergic receptor density and the humoral immune response in vivo and in vitro. Cell Immunol.117(2),339–351 (1988).
  Medline CASGoogle Scholar
• 212  Landmann R, Bittiger H, Buhler FR: High affinity β-2-adrenergic receptors in mononuclear leucocytes: similar density in young and old normal subjects. Life Sci.29(17),1761–1771 (1981).
  Medline CASGoogle Scholar
• 213  Loveland BE, Jarrott B, McKenzie IF: The detection of β-adrenoceptors on murine lymphocytes. Int. J. Immunopharmacol.3(1),45–55 (1981).
  Medline CASGoogle Scholar
• 214  Titinchi S, Clark B: α2-adrenoceptors in human lymphocytes: direct characterisation by [³H]yohimbine binding. Biochem. Biophys. Res. Commun.121(1),1–7 (1984).
  Medline CASGoogle Scholar
• 215  McPherson GA, Summers RJ: Characterization and localization of ³H-clonidine binding in membranes prepared from guinea-pig spleen. Clin. Exp. Pharmacol. Physiol.9(1),77–87 (1982).
  Medline CASGoogle Scholar
• 216  Goin JC, Sterin-Borda L, Borda ES et al.: Active α-2 and β-adrenoceptors in lymphocytes from patients with chronic lymphocytic leukemia. Int. J. Cancer49(2),178–181 (1991).
  Medline CASGoogle Scholar
• 217  Abrass CK, O’Connor SW, Scarpace PJ et al.: Characterization of the β-adrenergic receptor of the rat peritoneal macrophage. J. Immunol.135(2),1338–1341 (1985).
  Medline CASGoogle Scholar
• 218  Spengler RN, Allen RM, Remick DG et al.: Stimulation of α-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J. Immunol.145(5),1430–1434 (1990).
  Medline CASGoogle Scholar
• 219  Plaut M: Lymphocyte hormone receptors. Annu. Rev. Immunol.5,621–669 (1987).
  Medline CASGoogle Scholar
• 220  Yukawa T, Ukena D, Kroegel C et al.: β-2-adrenergic receptors on eosinophils. Binding and functional studies. Am. Rev. Respir. Dis.141(6),1446–1452 (1990).
  Medline CASGoogle Scholar
• 221  Hadden JW, Hadden EM, Middleton E: Lymphocyte blast transformation. I. Demonstration of adrenergic receptors in human peripheral lymphocytes. Cell Immunol.1(6),583–595 (1970).
  Medline CASGoogle Scholar
• 222  Melmon KL, Bourne HR, Weinstein Y et al.: Hemolytic plaque formation by leukocytes in vitro. Control by vasoactive hormones. J. Clin. Invest.53(1),13–21 (1974).
  Medline CASGoogle Scholar
• 223  Bourne HR, Lichtenstein LM, Melmon KL et al.: Modulation of inflammation and immunity by cyclic AMP. Science184(132),19–28 (1974).
  Medline CASGoogle Scholar
• 224  Depelchin A, Letesson JJ: Adrenaline influence on the immune response. I. Accelerating or suppressor effects according to the time of application. Immunol. Lett.3(4),199–205 (1981).
  Medline CASGoogle Scholar
• 225  Gader AM: The effects of β-adrenergic blockade on the responses of leucocyte counts to intravenous epinephrine in man. Scand. J. Haematol.13(1),11–16 (1974).
  Medline CASGoogle Scholar
• 226  Crary B, Borysenko M, Sutherland DC et al.: Decrease in mitogen responsiveness of mononuclear cells from peripheral blood after epinephrine administration in humans. J. Immunol.130(2),694–697 (1983).
  Medline CASGoogle Scholar
• 227  Dunn GP, Bruce AT, Ikeda H et al.: Cancer immunoediting: from immunosurveillance to tumor escape. Immunol. Nat.3,991–998 (2002).
  Medline CASGoogle Scholar
• 228  Saul AN, Oberyszyn TM, Daugherty C et al.: Chronic stress and susceptibility to skin cancer. J. Natl Cancer Inst.97(23),1760–1767 (2005).
  Medline CASGoogle Scholar
• 229  Greenfeld K, Avraham R, Benish M et al.: Immune suppression while awaiting surgery and following dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav. Immun.21,503–513 (2007).
  Medline CASGoogle Scholar
• 230  Kiecolt-Glaser JK, Fisher LD, Ogrocki P, Stout JC, Speicher CE, Glaser R: Marital quality, marital disruption, and immune function. Psychosom. Med.49,13–34 (1987).
  Medline CASGoogle Scholar
• 231  Zorilla EP, Luborsky L, McKay JR et al.: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun.15,199–226 (2001).
  MedlineGoogle Scholar
• 232  Irwin M: Psychoneuroimmunology of depression: clinical implications. Brain Behav. Immun.16(1),1–16 (2002).▪ Important review describing the impact of depression on mortality risk and its association with neuroimmune mechanisms.
  MedlineGoogle Scholar
• 233  Blomberg BB, Alvarez JP, Diaz A et al.: Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. J. Psychosom. Res.67,369–376 (2009).
  MedlineGoogle Scholar
• 234  Andersen BL, Farrar WB, Golden-Kreutz D et al.: Stress and immune responses after surgical treatment for regional breast cancer. J. Natl Cancer Inst.90(1),30–36 (1998).
  Medline CASGoogle Scholar
• 235  Thornton LM, Andersen BL, Crespin TR, Carson WE: Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav. Immun.21,185–194 (2007).
  MedlineGoogle Scholar
• 236  Thornton LM, Andersen BL, Carson WE 3rd: Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case–control analysis. Cancer Immunol. Immunother.57(10),1471–1481 (2008).
  Medline CASGoogle Scholar
• 237  Sephton SE, Dhabhar FS, Keuroghlian AS et al.: Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav. Immun.23(8),1148–1155 (2009).
  Medline CASGoogle Scholar
• 238  Lutgendorf SK, Sood AK, Anderson B et al.: Social support, psychological distress, and natural killer cell activity in ovarian cancer. J. Clin. Oncol.23(28),7105–7113 (2005).
  MedlineGoogle Scholar
• 239  Lutgendorf SK, Lamkin DM, DeGeest K et al.: Depressed and anxious mood and T-cell cytokine producing populations in ovarian cancer patients. Brain Behav. Immun.22,890–900 (2008).
  Medline CASGoogle Scholar
• 240  Glasner A, Avraham R, Rosenne E et al.: Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a β-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol.184(5),2449–2457 (2010).
  Medline CASGoogle Scholar
• 241  Basu S, Dasgupta PS, Lahiri T et al.: Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice. Life Sci.53(5),415–424 (1993).
  Medline CASGoogle Scholar
• 242  Basu S, Dasgupta PS, Chowdhury JR: Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. J. Neuroimmunol.60(1–2),1–8 (1995).
  Medline CASGoogle Scholar
• 243  Marttila RJ, Eskola J, Päivärinta M, Rinne UK: Immune functions in Parkinson’s disease. Adv. Neurol.40,315–323 (1984).
  Medline CASGoogle Scholar
• 244  Marttila RJ, Eskola J, Soppi E, Rinne UK: Immune functions in Parkinson’s disease lymphocyte subsets, concanavalin A-induced suppressor cell activity and in vitro immunoglobulin production. J. Neurol. Sci.69(3),121–131 (1985).
  Medline CASGoogle Scholar
• 245  Fiszer U, Piotrowska K, Korlak J et al.: The immunological status in Parkinson’s disease. Med. Lab. Sci.48(3),196–200 (1991).
  Medline CASGoogle Scholar
• 246  Villemain F, Chatenoud L, Galinowski A et al.: Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry146(5),609–616 (1989).
  Medline CASGoogle Scholar
• 247  Ganguli R, Brar JS, Chengappa KR et al.: Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch. Gen. Psychiatry52(8),668–672 (1995).
  Medline CASGoogle Scholar
• 248  Maes M, Bosmans E, Calabrese J et al.: Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res.29(2),141–152 (1995).
  Medline CASGoogle Scholar
• 249  Mortensen PB: The incidence of cancer in schizophrenic patients. J. Epidemiol. Commun. Health43(1),43–47 (1989).
  Medline CASGoogle Scholar
• 250  Goldacre M, Kurina L, Wotton C et al.: Schizophrenia and cancer: an epidemiological study. Br. J. Psychiatry187,334–338 (2005).
  MedlineGoogle Scholar
• 251  Asada M, Ebihara S, Numachi Y et al.: Reduced tumor growth in a mouse model of schizophrenia lacking the dopamine transporter. Int. J. Cancer123,511–518 (2008).
  Medline CASGoogle Scholar
• 252  Barak Y, Achiron A, Mandel M et al.: Reduced cancer incidence among patients with schizophrenia. Cancer104(12),2817–2821 (2005).
  MedlineGoogle Scholar
• 253  Antoni MH, Lutgendorf SK, Cole SW et al.: The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat. Rev. Cancer6(3),240–248 (2006).
  Medline CASGoogle Scholar
• 254  Perron L, Bairati I, Harel F et al.: Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control15(6),535–541 (2004).
  MedlineGoogle Scholar
• 255  Algazi M, Plu-Bureau G, Flahault A et al.: Could treatments with β-blockers be associated with a reduction in cancer risk? Rev. Epidemiol. Sante Publique52(1),53–65 (2004).
  Medline CASGoogle Scholar
• 256  Li CI, Malone KE, Weiss N et al.: Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer98(7),1504–1513 (2003).
  MedlineGoogle Scholar
• 257  Meier CR, Derby LE, Jick SS et al.: Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch. Intern. Med.160(3),349–353 (2000).
  Medline CASGoogle Scholar
• 258  Rosenberg L, Rao RS, Palmer JR et al.: Calcium channel blockers and the risk of cancer. JAMA279(13),1000–1004 (1998).
  Medline CASGoogle Scholar
• 259  Cao L, Liu X, Lin EJ et al.: Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell142(1),52–64 (2010).
  Medline CASGoogle Scholar
• 260  Khong HT, Restifo NP: Natural selection of tumor variants in the generation of ‘tumor escape’ phenotypes. Nat. Immunol.3,999–1005 (2002).
  Medline CASGoogle Scholar
• 261  Benish M, Bartal I, Goldfarb Y et al.: Perioperative use of β-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann. Surg. Oncol.15,2042–2052 (2008).
  MedlineGoogle Scholar